Sanofi (SNY,SAN.PA) said The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent or dupilumab for the treatment of bronchial asthma in children aged 6 to 11 years with severe or refractory disease whose symptoms are inadequately controlled with existing therapy. This expands the previous approval in Japan in this indication for patients aged 12 years and older.
The approval is based on data from the overall population and those with a type 2 inflammation phenotype in VOYAGE, a global phase 3 study evaluating Dupixent in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma.
Dupilumab is being jointly developed by Sanofi and Regeneron (REGN) under a global collaboration agreement.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.